Table 3.
Competitive inhibition assays using 11 different aCL antibody preparations with indicated recombinant B2GP1 and deletion mutants
| Antibody no. | 12345*
|
1- - - -
|
123- -
|
1234-
|
-2345
|
- -345
|
- - -45
|
- - - -5
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Max† | 50%‡ | Max | 50% | Max | 50% | Max | 50% | Max | 50% | Max | 50% | Max | 50% | Max | 50% | |
| 7104 | 90 | 0.8 | 90 | 1 | 98 | 1 | 90 | 0.7 | 10 | >57 | 20 | >50 | 5 | >40 | 0 | >47 |
| 6203 | 75 | 0.8 | 20 | >10 | 75 | 1 | 30 | >8 | 10 | >57 | 10 | >50 | 10 | >40 | 5 | >47 |
| 7008 | 90 | 0.2 | 40 | >10 | 80 | 0.4 | 50 | 8 | 20 | >57 | 20 | >50 | 20 | >40 | 20 | >47 |
| 6501 | 80 | 0.2 | 30 | >10 | 85 | 0.8 | 30 | >8 | 20 | >57 | 15 | >50 | 15 | >40 | 10 | >47 |
| 6626 | 80 | 0.3 | 50 | 10 | 90 | 0.8 | 40 | >8 | 18 | >57 | 20 | >50 | 15 | >40 | 10 | >47 |
| 6632 | 90 | 0.8 | 70 | 3 | 90 | 0.2 | 60 | 2 | 20 | >57 | 20 | >50 | 20 | >40 | 10 | >47 |
| 6644 | 90 | 0.2 | 45 | >10 | 90 | 0.7 | 50 | 8 | 10 | >57 | 10 | >50 | 10 | >40 | 10 | >47 |
| 7015 | 90 | 0.2 | 30 | >10 | 90 | 0.7 | 50 | 8 | 10 | >57 | 10 | >50 | 10 | >40 | 10 | >47 |
| 7101 | 80 | 0.8 | 20 | >10 | 70 | 3 | 20 | >8 | 5 | >57 | 5 | >50 | 5 | >40 | 5 | >47 |
| 6701 | 100 | 0.1 | 80 | 4 | 95 | 0.3 | 30 | >8 | 10 | >16 | 20 | >15 | 15 | >5 | 10 | >47 |
| 6641 | 96 | 0.1 | 98 | 10 | 60 | 4 | 60 | 2 | 20 | >16 | 10 | >15 | 20 | >5 | 10 | >47 |
>, Highest concentration tested.
*
Domains included in construct.
†
Maximum Inhibition observed at concentrations tested.
‡
Concentration (micromolar) to give 50% inhibition.